Why must aspirin stay at 75–100 mg with ticagrelor?

FDA BRILINTA labeling requires aspirin 75–100 mg once daily with ticagrelor. Maintenance doses above 100 mg reduce ticagrelor exposure and effectiveness. Nurses should question 325 mg BID or other high maintenance doses and notify the prescriber or pharmacist.

When should a nurse hold ticagrelor?

Hold for active pathological bleeding, history of intracranial hemorrhage (contraindicated), hypersensitivity, uncontrolled major hemorrhage, elective major surgery when antiplatelet effect is not desired (interrupt 5 days prior per label), or pending review when aspirin exceeds 100 mg daily or strong CYP3A drugs are added.

Can patients stop ticagrelor before a procedure on their own?

No. Labeling warns that stopping ticagrelor increases subsequent MI, stroke, and death. Only the prescriber should plan holds—typically interrupting 5 days before major bleeding-risk surgery when antiplatelet effect is not desired.

Is dyspnea on ticagrelor an emergency?

Mild dyspnea occurs in roughly 14–21% of patients in trials and labeling usually directs continuing ticagrelor unless intolerable. Assess for pulmonary edema, anemia, or PE if dyspnea is new, severe, or accompanied by hypoxia or hemodynamic change.

Why is a history of intracranial hemorrhage a contraindication?

BRILINTA labeling contraindicates ticagrelor in patients with a history of intracranial hemorrhage because of high recurrent bleeding risk. Do not administer or restart without specialist risk-benefit review.

What should patients report while on ticagrelor plus aspirin?

Teach patients to report bleeding that will not stop, red or black stools, pink or red urine, unusual bruising, severe headache, confusion, planned procedures, and breathing difficulty. Take ticagrelor twice daily and do not skip or double doses.

💊 P2Y12 Antiplatelet · DAPT Bleeding & Aspirin Cap

Ticagrelor: Nursing Drug Guide, Bleeding Risk & Aspirin Dosing

Ticagrelor (Brilinta) is a direct-acting P2Y12 inhibitor given twice daily with aspirin 75–100 mg after ACS—but the FDA boxed warning flags major bleeding on dual antiplatelet therapy, and aspirin doses above 100 mg reduce ticagrelor effectiveness. A history of intracranial hemorrhage is contraindicated, and stopping ticagrelor without a plan raises MI, stroke, and death risk. Before every dose, verify no active bleeding, reconcile concurrent antiplatelets and statins, confirm aspirin strength on the MAR, and treat falling hemoglobin, melena, or new neurologic change as stop-and-escalate events.

⏱️14 min read

📅Updated May 31, 2026

✓Pharmacist Reviewed

✍️

Written by

Sid A. Abdala Balal

🧪

Reviewed by

Kim Serra

Pharmacist

🚨 Boxed warning — bleeding on dual antiplatelet therapy

BRILINTA labeling carries a boxed warning for bleeding—like other antiplatelet agents, ticagrelor can cause significant, sometimes fatal hemorrhage, especially with concurrent aspirin, warfarin, or NSAIDs. Do not use ticagrelor with active pathological bleeding or a history of intracranial hemorrhage. Maintenance aspirin must be 75–100 mg daily; doses above 100 mg reduce ticagrelor effectiveness per FDA labeling. Do not stop ticagrelor without prescriber guidance—premature discontinuation increases subsequent cardiovascular events. If possible, manage bleeding without stopping the drug; when elective surgery requires loss of antiplatelet effect, interrupt ticagrelor 5 days before major bleeding-risk procedures when feasible.

📋 Contents

⚡ Quick facts

💊

Class

P2Y12 inhibitor (cyclopentyltriazolopyrimidine)

➡️

Route

Oral twice daily (BID)

📐

Usual ACS maintenance

90 mg BID (year 1); then 60 mg BID

⚠️

Main risk

Bleeding + aspirin >100 mg

💡 Key takeaway

On every MAR review, confirm ticagrelor 90 mg or 60 mg BID is paired with aspirin 75–100 mg once daily—not 325 mg or other high doses that blunt ticagrelor. Hold for active bleeding or ICH history, plan a 5-day perioperative interrupt when antiplatelet effect is not desired, and never let patients stop ticagrelor without a prescriber plan because ischemic events rise after abrupt discontinuation.

💊

Most common brand names

Ticagrelor is available as the brand Brilinta and as generic tablets per FDA labeling. Film-coated tablets are supplied as 60 mg and 90 mg strengths.

Always verify strength and schedule on the MAR—90 mg twice daily during the first year after ACS differs from 60 mg twice daily after one year or for high-risk coronary artery disease. Do not substitute clopidogrel or prasugrel without prescriber and pharmacy approval; P2Y12 inhibitors have different bleeding profiles, dosing intervals, and interaction rules.

🎯

Why we give it — Indications

Brilinta is a P2Y12 platelet inhibitor indicated for ischemic cardiovascular events when prescribed per FDA labeling. Nurses must match the indication to loading versus maintenance dosing, aspirin pairing, and treatment duration.

Use	Detail
Acute coronary syndrome / recent heart attack	Reduce thrombotic cardiovascular events in ACS or history of MI—given with aspirin 75–100 mg and often with heparin or enoxaparin per protocol
Angina within ACS	Medical or revascularization pathways for UA/NSTEMI/STEMI—verify loading sequence and aspirin cap on MAR
Chest pain / ACS admission	Loading 180 mg once, then first maintenance 90 mg at 6–12 hours, then 90 mg BID with aspirin per label
High-risk coronary artery disease	Patients with CAD and no prior stroke or MI—60 mg BID with aspirin 75–100 mg per labeling
Acute ischemic stroke or TIA	180 mg load, then 90 mg BID for up to 30 days with aspirin 75–100 mg once daily per label

On a small screen, swipe or scroll sideways to see the full table.

Do not start ticagrelor in patients undergoing urgent coronary artery bypass graft (CABG) surgery per labeling.

🔬

How it works

Ticagrelor is a direct-acting, reversible P2Y12 ADP receptor antagonist (cyclopentyltriazolopyrimidine)—it does not require hepatic activation like clopidogrel. Platelet inhibition begins quickly and requires twice-daily dosing because the effect is reversible. When combined with aspirin, both pathways of platelet activation are blocked, improving ischemic protection but amplifying bleeding. Aspirin maintenance doses above 100 mg daily reduce ticagrelor exposure and effectiveness per FDA labeling.

📐

Dosing overview

All ticagrelor regimens require concurrent aspirin 75–100 mg once daily. Ticagrelor may be taken with or without food per labeling.

ACS / history of MI

180 mg load → 90 mg at 6–12 h → 90 mg BID

Continue 90 mg BID through year 1; after 1 year, 60 mg BID per labeling

High-risk CAD (no prior stroke/MI)

60 mg BID

With aspirin 75–100 mg daily

Acute ischemic stroke / TIA

180 mg load → 90 mg BID ≤30 days

With aspirin 75–100 mg once daily

Aspirin co-therapy

75–100 mg daily only

Doses >100 mg reduce ticagrelor effectiveness per FDA label

Perioperative hold: Interrupt ticagrelor 5 days before surgery that carries major bleeding risk when loss of antiplatelet effect is desired per labeling.

Missed dose: Take the next dose at the scheduled time—do not double doses per labeling.

🛡️

Before you give it — Safety check

Pretreatment checks

History of intracranial hemorrhage—contraindicated; active pathological bleeding—contraindicated
Complete medication reconciliation—verify aspirin strength (75–100 mg cap), warfarin, NSAIDs, heparin/LMWH, and statin doses
Upcoming CABG or major surgery—confirm 5-day interrupt window and do not start before urgent CABG per label
Baseline bleeding assessment: bruising, gum bleeding, hematuria, melena, neurologic symptoms
Strong CYP3A inhibitors or inducers on MAR—notify pharmacist; check simvastatin/lovastatin dose ≤40 mg

Contraindications

History of intracranial hemorrhage (label section 4.1)
Active pathological bleeding such as peptic ulcer or intracranial hemorrhage (4.2)
Hypersensitivity to ticagrelor or any component (4.3)

Important interactions

Drug / class	Effect	Nursing action
Aspirin >100 mg daily	Reduces ticagrelor effectiveness per FDA labeling	Question high-dose aspirin on MAR; notify prescriber/pharmacist to adjust to 75–100 mg maintenance
Strong CYP3A inhibitors / inducers	Alter ticagrelor exposure—avoid concomitant use per label	Hold pending pharmacy review; document interaction check
Simvastatin or lovastatin >40 mg	Increased statin exposure and myopathy risk per label	Verify statin dose; notify pharmacist if above 40 mg with ticagrelor
Digoxin	Plasma digoxin levels may increase with ticagrelor initiation or dose change	Monitor digoxin levels and clinical toxicity per prescriber orders

On a small screen, swipe or scroll sideways to see the full table.

➡️

Administration

Oral tablet—60 mg or 90 mg per order; give twice daily on a consistent schedule
May give with or without food per label
Verify loading sequence (180 mg once, then 90 mg at 6–12 hours) during ACS admission
Coordinate aspirin administration—maintenance 75–100 mg once daily, not loading-scale doses long term
Missed dose: take next scheduled dose; do not double per labeling

📈

Expected therapeutic response

Reduced ischemic events in indicated populations—often not visible at bedside day-to-day
Stable vitals without new bleeding or neurologic change
Mild dyspnea may occur (~14–21% in trials)—usually continue ticagrelor per label unless severe or intolerable

Worsening chest pain, new neurologic deficits, falling hemoglobin, or hemodynamic change suggest bleeding or treatment failure—not simply expected antiplatelet bruising.

🚨

Red flags — Stop and act

Hold ticagrelor and escalate when any of the following appear.

Active pathological bleeding—blood in vomit, black stool, large-volume hemorrhage, or hemodynamic instability
Falling hemoglobin with tachycardia, pallor, or hypotension on dual antiplatelet therapy
New confusion, severe headache, or focal deficits—rule out intracranial bleeding; ICH history is a contraindication to restart
Blood in urine or epistaxis that will not stop—notify prescriber and trend hemoglobin
Aspirin dose above 100 mg on MAR with ticagrelor—notify prescriber/pharmacist same day to correct maintenance dose
Anaphylaxis or severe hypersensitivity—stop permanently

⚠️

Adverse effects

Adverse effect	Frequency / severity	Nursing response
Bleeding (major and minor)	Most common adverse reaction; fatal bleeding reported per label	Hold for pathological bleeding when ordered; monitor Hgb; supportive care per protocol
Shortness of breath (dyspnea)	~14–21% in PLATO; usually mild to moderate; often continues on drug per label	Assess severity and alternate causes; notify prescriber if new, severe, or worsening—usually continue ticagrelor unless intolerable
Bradyarrhythmias	Reported in clinical trials including syncope and AV block per label	Monitor heart rate and rhythm; notify prescriber for symptomatic bradycardia
Hypersensitivity / anaphylaxis	Reported postmarketing	Stop permanently; treat per anaphylaxis protocol
GI hemorrhage	Increased with antiplatelet combinations per label	Hold antiplatelets per orders; notify prescriber; GI evaluation
Hyperuricemia / gout	Reported in trials per label	Monitor symptoms; notify prescriber if acute gout flare

On a small screen, swipe or scroll sideways to see the full table.

☠️

Overdose and toxicity

There is no specific antidote for ticagrelor per FDA labeling. Platelet transfusion does not reverse ticagrelor’s antiplatelet effect. Overdose may increase bleeding risk; manage with supportive care for hemorrhage.

Management

Supportive care for bleeding; local protocol for transfusion and procedural hemostasis
Contact local poison control or medical toxicology services per facility protocol for large overdoses or life-threatening bleeding
Do not assume platelet transfusion restores normal clotting—label notes transfusion does not reverse ticagrelor

📞Poison control / toxicology

Contact your facility’s poison control or medical toxicology service per local protocol for suspected overdose or life-threatening bleeding on antiplatelet therapy.

🔤

Look-alike / sound-alike and error prevention

Ticagrelor vs clopidogrel vs prasugrel—all P2Y12 inhibitors but not interchangeable; confirm exact agent and BID vs daily schedule
Brilinta vs other brand names—verify full generic name on MAR
60 mg vs 90 mg tablets—independent double-check; year-1 ACS uses 90 mg BID, then 60 mg BID per label
Aspirin 81 mg vs 325 mg—maintenance must stay 75–100 mg with ticagrelor; high doses reduce drug effectiveness
Continue vs hold before surgery—default is 5-day interrupt for major bleeding-risk procedures when antiplatelet effect not desired

🛏️

Practical bedside notes

Topic	Bedside guidance
Dual antiplatelet therapy	Ticagrelor BID plus aspirin 75–100 mg is standard post-STEMI/NSTEMI—verify aspirin strength every shift; 325 mg BID is a common ordering error
Dyspnea	New mild dyspnea is common on ticagrelor—usually continue per label; assess for pulmonary edema, anemia, or PE if acute worsening
Procedure planning	Elective major surgery: interrupt 5 days when antiplatelet not desired; premature stop without plan increases ischemic risk
CABG timing	Do not start ticagrelor before urgent CABG per label—coordinate with cardiology and surgery
Ask pharmacy when	Aspirin dose above 100 mg, CYP3A drug added, statin above 40 mg with simvastatin/lovastatin, or bleeding on therapy

On a small screen, swipe or scroll sideways to see the full table.

👥

High-risk populations

Population	Considerations
History of intracranial hemorrhage	Contraindicated—do not administer or restart without specialist risk-benefit review
Older adults	Increased major bleeding on dual antiplatelet therapy—monitor Hgb and bleeding signs closely
Severe hepatic impairment	Avoid use per labeling
Active GI disease / prior ulcer	Active pathological bleeding is contraindicated; prior ulcer increases hemorrhage risk with antiplatelets
Pregnancy	Limited human data—use only if clearly needed per prescriber and label
Lactation	Breastfeeding not recommended per FDA labeling
Renal impairment	No dose adjustment required per label
Pediatric patients	Safety and effectiveness not established per label

On a small screen, swipe or scroll sideways to see the full table.

📊

Monitoring and documentation

Monitor

Signs of bleeding—GI, urinary, gingival, puncture sites, and neurologic change each shift
Serial hemoglobin / hematocrit when bleeding suspected or after invasive procedures
Aspirin dose on MAR—flag maintenance doses above 100 mg for pharmacy review
Dyspnea onset and severity—distinguish expected ticagrelor dyspnea from pulmonary emergency
Digoxin levels when ticagrelor starts or dose changes if patient takes digoxin

Document

Loading dose time and strength (180 mg load, 90 mg at 6–12 h)
Concurrent aspirin dose and any anticoagulant or NSAID
Hold reason, prescriber notification, and bleeding workup results
Perioperative interrupt and planned restart dates

💬

Patient teaching

Take ticagrelor exactly as ordered—twice daily—and do not stop without prescriber guidance because early discontinuation raises heart attack, stroke, and death risk per label
Aspirin must stay at the prescribed maintenance dose (usually 75–100 mg daily)—do not take extra aspirin or high-dose products without prescriber approval
Report bruising, bleeding that will not stop, red or black stools, pink urine, severe headache, confusion, or new breathing difficulty promptly
Mild shortness of breath can occur on ticagrelor—tell the team if it is severe or sudden
Tell dentists, surgeons, and clinicians about ticagrelor and aspirin before any procedure

✋

The Hold Rule

✋ The Hold Rule — When to pause and clarify

Active pathological bleeding (peptic ulcer bleeding, intracranial hemorrhage, major GI hemorrhage)
History of intracranial hemorrhage—contraindicated; do not administer
Hypersensitivity or anaphylaxis to ticagrelor
Major bleeding-risk surgery within 5 days when antiplatelet effect is not desired—coordinate per label
Aspirin maintenance above 100 mg with ticagrelor—hold and clarify with prescriber/pharmacist before next dose
Strong CYP3A inhibitor or inducer added without pharmacy review

STEMI and urgent PCI pathways may require continued antiplatelet therapy despite bleeding risk—follow prescriber, cardiology, and institutional protocol. If possible, manage bleeding without stopping ticagrelor per labeling.

🩺

Clinical practice integration and workflow

Ticagrelor safety is a reconciliation and aspirin-dose problem as much as a BID scheduling problem—dual antiplatelet therapy, high-dose aspirin errors, and perioperative interrupts collide on busy cardiac units.

1. Check-before-you-give protocol

Right patient, drug, dose (60 vs 90 mg), route, time—and allergy status
Confirm no active bleeding, no ICH history, and surgery schedule within 5 days
Reconcile aspirin strength (75–100 mg cap), warfarin, heparin, NSAIDs, and statin doses
Verify BID times are spaced consistently—missed doses are not made up by doubling

2. High-alert and safety badge

Dual antiplatelet bleeding risk — verify aspirin ≤100 mg and trend Hgb

Treat new melena, hemodynamic change, or falling hemoglobin as urgent—not routine antiplatelet bruising or expected mild dyspnea alone.

3. Clinical workflow: hold and question rules

Hold for active bleeding and notify prescriber before next dose
Question aspirin 325 mg or other doses above 100 mg on ticagrelor without pharmacy approval
Flag elective procedures scheduled within 5 days of last dose when antiplatelet effect must be reduced

4. Critical teach-back questions

“What bleeding signs should you report?” (Black stools, vomit blood, severe headache, confusion, bleeding that will not stop.)
“Can you stop ticagrelor before dental surgery on your own?” (No—stopping raises ischemic risk; prescriber plans hold when needed.)

5. Care coordination

Pharmacist: Aspirin dose cap, CYP3A interactions, statin dose limits, perioperative interrupt/restart, and transition to another P2Y12 inhibitor when ordered.

Cardiology / surgery: Balance ischemic protection vs bleeding for procedures; document shared decision in chart.

🧠 Quick mental checklist

Is the patient on ticagrelor BID plus aspirin—and is aspirin ≤100 mg daily?
Any active bleeding, falling Hgb, or neurologic change?
History of intracranial hemorrhage documented?
Elective major surgery within 5 days—was ticagrelor interrupted per orders?
Was the 180 mg load and 6–12 h 90 mg dose given before maintenance BID in ACS?

📚

Ticagrelor NCLEX practice questions

Practice NCLEX-style clinical judgment practice for ticagrelor with a tabbed case (MAR, labs, vitals, nursing notes), then priority action, SATA cue recognition, lab-trend interpretation, matrix urgency sorting, perioperative judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes, with emphasis on the aspirin 75–100 mg cap and DAPT bleeding risk.

Select a tab to view MAR, labs, vitals, and nursing note details for this case.

MAR — today

Ticagrelor 90 mg PO BID — morning dose given 0800; due 2000
Aspirin 325 mg PO BID — both doses given yesterday and 0800 today (per outdated order set)
Metoprolol 25 mg PO BID — given 0800
Simvastatin 20 mg PO at bedtime
Elective knee replacement scheduled in 6 days

Question 1 — Priority action

After reviewing the case tabs, what is the nurse’s best FIRST action at 1400 when the post-STEMI patient has falling hemoglobin, positive stool guaiac, aspirin 325 mg BID on the MAR, and ticagrelor held pending prescriber callback?

Administer scheduled ticagrelor 90 mg because STEMI protocol requires BID dosing Hold ticagrelor and aspirin, notify prescriber/pharmacist, escalate bleeding pathway, and request aspirin adjustment to 75–100 mg maintenance per labeling Increase aspirin to 325 mg TID to improve antiplatelet effect while continuing ticagrelor Document dyspnea as expected ticagrelor effect and continue routine care until orthopedics evaluates knee surgery

Question 2 — Recognize cues

Which findings from the case tabs support concern for bleeding or a ticagrelor–aspirin safety error on dual antiplatelet therapy? Select all that apply.

Select all that apply

Hemoglobin 13.8 → 10.6 g/dL over 3 days with guaiac-positive stools Aspirin 325 mg BID co-ordered with ticagrelor 90 mg BID HR 108, BP 102/64, pallor, and new dyspnea at rest Stable platelets 198 ×10⁹/L without schistocytes Simvastatin 20 mg at bedtime (within 40 mg limit with ticagrelor)

Question 3 — Trend interpretation

After ticagrelor and aspirin are held, prescriber orders aspirin 81 mg daily and GI consult, evening data show:

Trend snapshot
Hgb 10.6 g/dL (stable); HR 98; BP 108/70; no melena reported
Dyspnea improved to mild with activity only; SpO₂ 97% on room air
Aspirin 81 mg given 1800; ticagrelor still held pending gastroenterology
Knee surgery postponed; cardiology notified for DAPT plan

Select all that apply — which nursing actions are appropriate now?

Continue serial hemoglobin checks, orthostatics, and bleeding assessments per protocol Resume ticagrelor 90 mg BID immediately because dyspnea improved Document holds, aspirin dose correction, and multidisciplinary notifications in the record Reinforce bleeding precautions and teach signs requiring immediate escalation Restart aspirin 325 mg BID to maintain dual antiplatelet intensity

Question 4 — Matrix judgment

For each finding, select the best nursing urgency category (one per row).

Finding	Expected — document and continue monitoring	Concerning — notify prescriber/pharmacist	Requires immediate follow-up
Day 2 post-STEMI; aspirin 81 mg daily; ticagrelor 90 mg BID on time; Hgb stable; no bleeding
Aspirin 325 mg BID ordered with ticagrelor on MAR without pharmacy review
Hgb 10.6 g/dL with guaiac-positive stool, tachycardia, and hypotension on DAPT
New mild dyspnea day 3 on ticagrelor without hypoxia or hemodynamic change

On a small screen, swipe or scroll sideways to see the full table.

Question 5 — Perioperative hold

A patient on ticagrelor 90 mg BID has elective hip replacement scheduled in 4 days. The surgeon wants minimal antiplatelet effect. What is the nurse’s best action today?

Confirm prescriber/anesthesia plan to interrupt ticagrelor at least 5 days before surgery per labeling and document interrupt/restart orders with cardiology Continue ticagrelor until the morning of surgery because one missed dose reverses platelets Hold ticagrelor permanently without notifying cardiology because orthopedic surgery is higher priority Switch to aspirin 325 mg TID to replace ticagrelor before surgery

Question 6 — Documentation cloze

When ticagrelor is co-prescribed with aspirin, the nurse documents maintenance aspirin because doses above 100 mg reduce ticagrelor effectiveness.

Answer key & rationale

Next step Timed NCLEX Next Gen–style scenarios on NurseOnShift

❓

Frequently asked questions

📚

References

🔐

Review and transparency

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, or institutional protocols.

Ticagrelor: Nursing Drug Guide, Bleeding Risk & Aspirin Dosing

📋 Contents

⚡ Quick facts

💡 Key takeaway

Most common brand names

Why we give it — Indications

How it works

Dosing overview

Before you give it — Safety check

Pretreatment checks

Contraindications

Important interactions

Administration

Expected therapeutic response

Red flags — Stop and act

Adverse effects

Overdose and toxicity

Management

Look-alike / sound-alike and error prevention

Practical bedside notes

High-risk populations

Monitoring and documentation

Monitor

Document

Patient teaching

The Hold Rule

Clinical practice integration and workflow

1. Check-before-you-give protocol

2. High-alert and safety badge

3. Clinical workflow: hold and question rules

4. Critical teach-back questions

5. Care coordination

🧠 Quick mental checklist

Ticagrelor NCLEX practice questions

Answer key & rationale

Frequently asked questions

Why must aspirin stay at 75–100 mg with ticagrelor?

When should a nurse hold ticagrelor?

Can patients stop ticagrelor before a procedure on their own?

Is dyspnea on ticagrelor an emergency?

Why is a history of intracranial hemorrhage a contraindication?

What should patients report while on ticagrelor plus aspirin?

References

Related Topics

Clopidogrel

Deep Vein Thrombosis

Anemia

Medication Administration

Complete Blood Count

Apixaban

Review and transparency